PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept

NCT02681783 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Central Serous Chorioretinopathy
Age Related Macular Degeneration
Idiopathic Poplypoidal Choroidal Vasculopathy

Interventions

DRUG: aflibercept

Sponsor

Sunnybrook Health Sciences Centre